NICE Pathways - warwick.ac.uk · •To provide seamless, customer-centric access to our vast content ... (2012) Liraglutide for type 2 diabetes. NICE technology appraisal guidance

NICE Pathways

Judith Richardson, Associate Director, Health and Social Care

Digital Health: design: develop: deploy: evaluate

Warwick

25th July 2013

Overview

• The context for NICE Pathways

• Why pathways?

• What are NICE pathways?

• Where are we up to?

• What’s the future?

NICE audiences… an expanding

remit

• Social care audience

• Local government, for

social care and public

health

Trends in the market

• Rapid uptake of mobile devices as the platform

to access evidence

• Expectation that evidence is integrated at the

point of care

• Social media and on-line networking

• Open access, big data

NICE Digital Strategy

• To provide seamless, customer-centric access to

our vast content

• Within cost effective and affordable systems

Our digital system vision

Key access routes to date

Why pathways – what was the

issue? • A lot of guidance

• Different guidance programmes

• Difficult to find all relevant information on a

given topic

• Not always easy to see how guidance

from different programmes fits together

• No linking across related topics

Being part of the solution

• Which mirror the experience of health professionals..

• And make them accessible through NHS Evidence and the NICE website

• That follow a sequence of decisions/events..

• We array our guidance along a series of pathways..

Prevention Diagnosis

Treatment Rehabilitation/

palliation

What are NICE pathways?

• Bring together related

guidance, between and

within topics

• Link other products –

Quality Standards,

implementation support

tools etc

• Provide a useful format for

multiple audiences – a

network of NICE information

Easier quicker access to the

evidence

Overview of the Depression Pathway

Links to other information

Ways to access NICE Pathways http://pathways.nice.org.uk/

Preventing type 2 diabetes: population

and community interventions. NICE public

health guidance 35 (2011)

Preventing type 2 diabetes: risk

identification and interventions for

individuals at high risk. NICE public health

guidance 38 (2012)

NICE public health guidance

Type 1 diabetes. NICE clinical guideline 15

(2004)

Diabetes in pregnancy. NICE clinical

guideline 63 (2008)

Type 2 diabetes footcare. NICE clinical

guideline 10 (2004)

Diabetic foot problems: inpatient

management. NICE clinical guideline 119

(2011)

Type 2 diabetes – newer agents. NICE

clinical guideline 87 (2009)

NICE clinical guidelines

Long-acting insulin analogues. NICE

technology appraisal guidance 53 (2002)

Patient education models. NICE technology

appraisal guidance 60 (2003)

Insulin pump therapy. NICE technology

appraisal guidance 151 (2008)

Intravitreal implant for macular oedema. NICE

technology appraisal guidance 271 (2013)

Ranibizumab for macular oedema. NICE

technology appraisal guidance 274 (2013) Exenatide for type 2 diabetes. NICE technology

appraisal guidance 248 (2012)

Liraglutide for type 2 diabetes. NICE

technology appraisal guidance 203 (2010)

Long-acting insulin analogues. NICE

technology appraisal guidance 53 (2002)

Patient education models. NICE technology

appraisal guidance 60 (2003)

NICE technology appraisals

Intravitreal implant for macular oedema. NICE

technology appraisal guidance 271 (2013)

Ranibizumab for macular oedema. NICE

technology appraisal guidance 274 (2013)

Allogeneic pancreatic islet cell transplant for

type 1 diabetes. NICE interventional procedure

guidance 257 (2008)

NICE interventional procedures

Where are we up to?

• 125 pathways

• 80% of clinical guidelines

• 95% of public health guidance

• 90% of quality standards

• 45% overall (includes guidance on drugs

and procedures)

What’s the future?

• 90% of guidance accessible by end of

2013/14

• Network of evidence and other supporting

information

• Incorporation of social care

• Improved presentation and function

Feedback from users...... “I’m impressed by the wide and

growing coverage of

pathways” Ambulance trust

operations manager

“We use NICE pathways

extensively and they are

very easy to use and

navigate, and provide

helpful information in a

useful format”. Public

health team

“NICE pathways are very

helpful. They are more

"enticing" than the

guidance”. Social care team “I think you just made NICE

easier for us." Pathways

user